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hematologic malignancies >2 years post HSCT (39 with
cGVHD; 15 without cGVHD). In patients without cGVHD, BH3
priming was similar in Treg, Tcon and CD8. In contrast, Treg
and CD8 were more primed than Tcon in cGVHD when
challenged with BIM, BAD, PUMA, BMF and BAD + NOXA
peptides. In patients with cGVHD, Treg expressed higher
levels of Bim, BclxL and CD95 and lower levels of Bcl-2, but
there was no signiﬁcant difference in Mcl1. Consistent with
these observations, Treg were more susceptible than Tcon
and CD8 to both mitochondrial and death receptor pathway
apoptosis in vitro. Increased Treg susceptibility to apoptosis
in cGVHD therefore appears to be mediated primarily by
increased expression of CD95 and Bim and lower levels of
Bcl-2. Although Treg priming was increased overall in
cGVHD, examination of Treg in severe cGVHD actually
revealed less priming in this subset. This correlated with
increased Treg expression of Bcl-2 and Mcl1. Since the total
number of Treg is signiﬁcantly reduced in severe cGVHD,
these ﬁndings suggest that the remaining Treg are relatively
resistant to the mitochondrial pathway of apoptosis.
However, CD95 expression in Treg remains high in severe
cGVHD indicating persistent high-level apoptosis mediated
through the death receptor pathway. Administration of low
dose IL-2 to patients with severe cGVHD led to increased
expression of Bcl-2 and less susceptibility to both mito-
chondrial and death receptor pathway apoptosis. These
studies help deﬁne the complex and distinct pathways that
regulate survival in different T cell subsets, and changes in
these pathways that occur in patients with chronic GVHD.
These pathways play important roles in the maintenance of T
cell homeostasis and targeting these complex pathways can
provide new opportunities to promote immune tolerance
after allogeneic HSCT.57
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Background: Graft versus host disease (GVHD) and
infectious complications are major limiting factors to the
success of allogeneic (allo) hematopoietic cell trans-
plantation (HCT). CMV reactivation and disease lead to
morbidity and mortality, and potentially promote GVHD.
Primary infection commonly leads to latency, and viral
replication can be reactivated in the immunocompromised
state. Using a low mortality/low GVHD severity murine HCT
model, we assessed for a contributory role of MCMV in GVHD
development.
Methods: BALB/c mice were infected with either Smith
strain murine CMV (MCMV) (3104 PFU) or mock and
monitored for 24 weeks to establish latency. CMV seroposi-
tivity was conﬁrmed and HCTwas performed using sublethal
TBI (750cGy single dose) followed by i.v. administration of
7106 bonemarrow cells plus 3106 splenocytes from either
syngeneic (syn) BALB/c or allo B10.D2 donors. Recipients
were observed for survival and clinical GVHD. At day +100,lung, liver, gut, spleen were collected in surviving animals
and analyzed for pathology and cytokine expression; BALF
cellularity was assessed. Engraftment of allo donor cells was
conﬁrmed by PCR for D2Mit265 gene product size of 139bp
(BALB/c) versus 103bp (B10.D2) in recipient's splenic DNA, all
allo recipients being at least 60% donor chimera.
Results: Mortality (26.3 vs. 8.3%) and GVHD severity in allo
MCMV preinfected recipients was higher than in allo mock
controls. All syn recipients survived without evidence of
clinical disease. To assess the contribution of MCMV latency
and reactivation to GVHD pathology, allo recipients were
stratiﬁed by using MCMV IE1 gene expression at time of
analysis as an indicator for active replication. Pathologic
changes of lung and liver GVHD in IE-1+ recipients were
signiﬁcantly increased compared tomock controls (P< 0.01),
and were only slightly increased in IE-1-. None of the
changes were characteristic of active viral disease. No
signiﬁcant gut injury was seen in allo recipients and no
differences in pathology were seen among syn groups. In
IE1+ allo recipients, total cell and total CD4+ (but not CD8+) T
cell count in BALF were increased (p<0.05) when compared
with mock controls, as were protein expression of lung IFN-
gamma and liver TNF (p<0.05).
Conclusion: MCMV IE-1 expression indicating replicative
CMV reactivation is associated with increased GVHD severity
and strengthens the concept of CMV being not only a path-
ogen of potentially lethal viral disease but also as a driving
factor in GVHD development.58
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The placenta protects the fetus from the mother's
immune system. We have previously found that fetal
membrane cells (FMCs) isolated from term placenta prevent
alloreactivity in vitro. FMCs share many features with bone
marrow-derived mesenchymal stromal cells (MSCs), which
we previously introduced to treat severe acute graft-versus-
host disease (GVHD). Here, we tested FMCs for treatment of
steroid-refractory acute GVHD.
After two passages in culture, approximately 109 FMCs
were obtained from one single placenta, although not all
cells from passage 0 and passage 1 were used for expansion.
The FMCs were positive for CD29, CD44, CD73, CD90, CD105,
and CD49d but were negative for hematopoietic, endothelial,
and epithelial markers. Microsatellite polymorphism anal-
ysis showed that FMCs were of maternal origin. All FMCs
used showed normal karyotype.
Nine patients who had undergone hematopoietic stem
cell transplantation and who had developed steroid-refrac-
tory grade IIIeIV acute GVHDwere given 0.9e2.8 x 106 FMCs/
kg at 15 infusions. Median age was 57 years. There was no
Abstracts / Biol Blood Marrow Transplant 19 (2013) S129eS149S142toxicity from infusion of FMCs. Two of eight evaluable
patients had a complete response and four had a partial
response, giving an overall response rate of 75%. Three
patients are alive from 6 to 21 months after HSCT. One
patient is well and two have chronic GVHD. Two patients
showed no response at all.
Thus, FMCs may be successfully used for immune
modulation and tissue repair.Table 1
ST2 concentrations at D14 predict GVHD development by D100 and predict
D180 NRM
UM FIC (n ¼ 414) UM RIC
(n ¼ 184)
DFCI
(n ¼ 75)
Hazard
Ratio
(HR)
P-
value
HR P-
value
HR P-
value
Age (55 and
Over vs.
Under 55)
1.5 0.01 0.8 0.4 0.1 0.02
Disease Status
(High vs.
Low risk)
1.0 0.99 1.8 0.02 n/a
Donor 1.9 <0.001 0.9 0.7 n/a59
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Fungal infection is a serious complication after allogeneic
hematopoietic stem cell transplantation but its impacts on
graft-versus host disease (aGVHD) remains to be elucidated.
a-mannan, one of the main components of fungal cell wall,
induces Th17 responses, leading to the elimination of fungi.
We therefore hypothesized that fungal infection could
modulate GVHD by inducing Th17 responses. Lethally irra-
diated B6D2F1 (H-2b/d) mice were injected with 4 x 106 BM
and 4 x 106 T cells from MHC-mismatched B6 (H-2b) donors
on day 0. Mice were intraperitoneally injected with 20mg of
a-mannan or diluent on day 1. GVHD was severe in mannan-
treated allogeneic mice, with 16.7% survival by day30,
whereas 83.3% of allogeneic controls survived this period
(Table). Histopathologic examination showed signiﬁcantly
exacerbation of GVHD pathology, especially in the lung, of
mannan-treated animals than in controls (Table).
A ﬂowcytometric analysis of the spleen and thymus after
BMT showed that administration of mannan did not alter
donor cell engraftment.
We then evaluated the roles of Th17 in aGVHD of
mannan-treated allogeneic models using IL-17-deﬁcient
mice as donors. Infusion of IL-17-/- T cells signiﬁcantly
improved GVHD clinical scores (3.5 0.4 vs 5.50.3 at day14,
P<.05), survival (62.5% vs 12.5% at day 30, P < .05) and
pulmonary GVHD pathology scores (1.00.5 vs 7.01.0 at
day21, P < .05) compared with those of mannan-treated
controls.
These results suggest that mannan can exacerbate acute
GVHD, mainly on pulmonary lesions.Th17 contribute to the
development of acute pulmonary GVHD in this model, and
that targeting Th17 may therefore represent a promising
therapeutic strategy for treating acute pulmonary GVHD.Table
Group Clinical
GVHD
scores
on
day+14
Survivals
on
day+30
(%)
Pathology Scores
Lung Liver Intestine
TCD Diluent 1.10.8 100 0 0.30.4 0.70.4
TCD a-mannan 1.20.5 100 0 0.70.8 0.50.5
+T Diluent 3.60.7 83.3 1.50.7 2.5 1.2 2.0 0.8
+T a-mannan 5.70.5y 16.7* 7.01.0y 4.0 1.8 2.5 0.8
TCD: T cell-depleted BMT, +T: T cell-repleted BMT.
Data are expressed as mean  SD.
* P < 0.01 vs control.
y P<0.05 vs control.60
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Acute GVHD is the primary limitation of allogeneic HSCT.
We have previously reported that plasma concentrations of
suppressor of tumorigenicity 2 (ST2) at the onset of GVHD
therapy predicted response at day (D) 28 and non-relapse
mortality (NRM) at D180 after therapy initiation. We
hypothesized that ST2measured early in HSCTwould predict
GVHD occurrence by D100 and D180 NRM after HSCT.
We measured ST2 in plasma taken at D0, D14 and D21
after HSCT in a pilot set. ST2 concentrations at D14weremost
different between patients who developed GVHD and those
without GVHD, and were twice higher in patients receiving
full intensity conditioning (FIC) compared to those receiving
reduced intensity conditioning (RIC). We then measured ST2
concentrations at D14 in two independent sets: 1) 598
patients from the University of Michigan (UM), 69% receiving
FIC (15% receiving TBI) and 31% receiving RIC HSCT, 2) 75
patients receiving unrelated, FIC (92% receiving TBI) HSCT
from the Dana Farber Cancer Institute (DFCI). UM patients
who developed GVHD were older and more likely to receive
mismatched or unrelated donor HSCT. Median day of GVHD
onset was D35 in FIC and D42 in RIC (p¼0.08). DFCI patients
who received sirolimus as GVHD prophylaxis were over-(Unrelated
vs. Related)
HLA match
(Mismatched
vs. Matched)
2.1 <0.001 1.0 0.9 2.7 0.09
ST2 Concentration
(High vs.
Low)*,y
1.5 0.004 1.3 0.3 2.0 0.08
Age 3.1 <0.001 0.7 0.4 0.7 0.5
Disease Status 1.1 0.6 2.7 0.02 n/a
Donor 1.5 0.1 1.1 0.8 n/a
HLA match 1.7 0.06 0.5 0.3 1.9 0.2
ST2 Concentration 2.8 <0.001 4.8 0.005 2.6 0.04
* Effect of ST2 calculated with regression models adjusting for age,
disease status, donor, and HLA match.
y High deﬁned as ST2 concentration >600 pg/mL for UM FIC, >300 pg/mL
for UM RIC, >1660 pg/mL for DFCI.
